Michael Sabina

Dr. Michael Sabina

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Sabina
Michael Sabina
SSShrinand Shah
Shrinand Shah
MGMason Grimm
Mason Grimm
JDJean Carlo Daher
Jean Carlo Daher
PCPaola Campillo
Paola Campillo
ABAnas Bizanti
Anas Bizanti
Background: The benefit of beta-blockers (BBs) for myocardial infarction (MI) patients with a preserved left ventricular ejection fraction (LVEF) is uncertain. While beneficial for a reduced LVEF, their efficacy with a preserved LVEF, especially with modern revascularization, is unclear. Methods: A PRISMA-guided systematic review and meta-analysis utilized PubMed and EMBASE. Three randomized controlled trials comparing outcomes in MI patients with a preserved LVEF treated with BBs versus no treatment were included. The primary outcome was composite all-cause mortality and MI; secondary outcomes were all-cause mortality, cardiovascular mortality, MI, and stroke. Results: Three studies, including a total of 9512 participants, were analyzed. Beta-blockers did not demonstrate a statistically significant benefit in reducing the composite endpoint of all-cause mortality and myocardial infarction (RR 0.97, 95% CI: 0.84–1.12, p = 0.671, I2 = 0%). Similarly, no significant effect was observed for secondary outcomes: all-cause mortality (RR 0.96, 95% CI: 0.79–1.17, p = 0.708), cardiovascular mortality (RR 1.22, 95% CI: 0.87–1.72, p = 0.247), myocardial infarction (RR 0.97, 95% CI: 0.78–1.19, p = 0.759), and stroke (RR 0.96, 95% CI: 0.66–1.38, p = 0.819). Conclusions: In patients with myocardial infarction and a preserved LVEF, beta-blockers did not significantly reduce mortality, recurrent myocardial infarction, or stroke, suggesting a limited benefit in this population under contemporary management protocols.

4 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Sabina
Michael Sabina
ZBZein Barakat
Zein Barakat
AFAdrian Feliciano
Adrian Feliciano
ALAndrew Lamb
Andrew Lamb
MAM Mrhaf Alsamman
M Mrhaf Alsamman
Background: Heart failure (HF) patients often experience persistent fluid overload despite standard diuretic therapy. The adjunctive use of acetazolamide, a carbonic anhydrase inhibitor, in combination with loop diuretics has shown promise in improving decongestion and diuretic efficacy. This literature review aims to analyze six studies evaluating the effectiveness of acetazolamide as an additive treatment for acute decompensated heart failure (ADHF) and its impact on various outcomes. Methods: We searched the PubMed database using the terms “acetazolamide heart failure”. We refined our search with specific filters (as shown our PRISMA flow diagram) and exclusion criteria, narrowing down our results to five studies. We included an extra study via expert recommendation, ultimately including six studies for comprehensive analysis. Results: The review highlights the positive effects of acetazolamide on decongestion, natriuresis, and diuresis in HF patients. However, it also showcases the limitations of these trials. Discussion: While the reviewed studies demonstrate the potential benefits of acetazolamide in enhancing decongestion and diuretic efficiency, there are limitations to consider, including small sample sizes, lack of blinding, and limited external validity. Further research is needed to confirm these findings, compare acetazolamide with other diuretic combinations, and explore its effects in a broader population of heart failure patients, including those in the United States. The use of acetazolamide in HF management warrants continued investigation to optimize its role in improving decongestion and patient outcomes.

4 January 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
JRJuan Carlos Rivera-Martinez
Juan Carlos Rivera-Martinez
MSMichael Sabina
Michael Sabina
AKAqeel Khanani
Aqeel Khanani
ALAndrew Lurie
Andrew Lurie
ARAmanda Rigdon
Amanda Rigdon
TPTimir K. Paul
Timir K. Paul
Purpose Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations. Methods A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone’s cardiovascular and renal effects. Three RCTs were included—FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF—encompassing 19,027 participants. Primary outcomes included cardiovascular death, HF hospitalization, and renal failure. Secondary outcomes focused on safety and adverse events like acute kidney injury and hyperkalemia. Meta-analyses were performed using hazard ratios (HR), confidence intervals (CI), and Relative Risk (RR). Results Finerenone was associated with a 20% reduction in HF hospitalization risk (HR 0.80, 95% CI: 0.72–0.90) and a 14% reduction in all-cause mortality (RR 0.86, 95% CI: 0.77–0.97). Finerenone did not significantly reduce cardiovascular death (HR 0.91, 95% CI: 0.82–1.01, p = 0.06). Renal failure rates were similar between Finerenone and placebo (RR 1.05, 95% CI: 0.65–1.68). Hyperkalemia incidence was significantly higher with Finerenone, with a RR of 2.31 (95% CI: 1.98–2.69). Conclusion This meta-analysis shows that Finerenone significantly reduces HF hospitalizations and all-cause mortality in patients with chronic kidney disease and heart failure. Further studies are needed to clarify its effects on cardiovascular death and renal failure.

1 February 2024 in Cardiology Research
Verified
Journal Article
Open access
PDF file
MSMichael Sabina
Michael Sabina
MAM. Mrhaf Alsamman
M. Mrhaf Alsamman
Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health

4 August 2024 in Current Problems in Cardiology
Verified
Journal Article
Closed access
MSMichael Sabina
Michael Sabina
JRJuan Carlos Rivera-Martinez
Juan Carlos Rivera-Martinez
AKAqeel Khanani
Aqeel Khanani
ARAmanda Rigdon
Amanda Rigdon
POPhilip Owen
Philip Owen
JMJoseph Massaro
Joseph Massaro

25 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Sabina
Michael Sabina
JTJennifer Trube
Jennifer Trube
SSShrinand Shah
Shrinand Shah
ALAndrew Lurie
Andrew Lurie
MGMason Grimm
Mason Grimm
ABAnas Bizanti
Anas Bizanti
Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal side effects and hyperkalemia, Finerenone selectively binds to mineralocorticoid receptors, reducing these risks. Recent randomized controlled trials have demonstrated Finerenone’s potential to improve cardiovascular outcomes, making it a promising alternative in the management of heart failure and other cardiovascular conditions associated with CKD and T2D. Methods: We conducted a scoping review using PRISMA guidelines. A search for “Finerenone” in the PubMed, Embase, and Cochrane Library databases included randomized controlled trials (RCTs), post hoc analyses, and relevant meta-analyses on cardiovascular outcomes. Data were synthesized narratively, assessing study quality through strengths and limitations. Discussion: Finerenone has shown significant benefits and a superior safety profile compared with traditional MRAs like spironolactone and eplerenone in managing CKD, T2D, and heart failure. It effectively reduces cardiovascular and renal events while minimizing risks such as hyperkalemia and hormonal side effects associated with steroidal MRAs. Future studies, including the REDEFINE-HF, FINALITY-HF, and CONFIRMATION-HF trials, will further explore Finerenone’s potential across diverse heart failure phenotypes, including its role in heart failure with mildly reduced and preserved ejection fractions, potentially establishing it as a cornerstone therapy in heart failure management. Conclusions: Finerenone represents a significant advancement in MRA therapy, offering enhanced safety and efficacy in managing cardiovascular outcomes in CKD and T2D patients. The current evidence supports its use as a promising alternative to traditional MRAs, particularly in patients intolerant to steroidal MRAs. Further trials are needed to fully establish its potential across diverse patient populations, including those with varying heart failure phenotypes.